CBU
AKBA icon

CIBC Bancorp USA’s Akebia Therapeutics AKBA Stock Holding History

CIBC Bancorp USA’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3K Buy
14,267
+1,517
+12% +$1.81K ﹤0.01% 1920
2026
Q1 		$17.7K Buy
+12,750
New +$17.5K ﹤0.01% 1741
2025
Q3 		$72.8K Buy
+26,650
New +$88.7K ﹤0.01% 1387

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CIBC Bancorp USA's AKBA Position: Q2 2026 in Review

CIBC Bancorp USA increased its Akebia Therapeutics (AKBA) stake by 12% in Q2 2026, buying an estimated $1.81K and bringing the position to 14,267 shares worth $16.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1920.

CIBC Bancorp USA first reported a position in AKBA in Q3 2025 and has held it in 3 quarters since. The position peaked at $72.8K in Q3 2025. 155 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • CIBC Bancorp USA held 14,267 shares of Akebia Therapeutics worth $16.3K as of Q2 2026.
  • CIBC Bancorp USA bought 1,517 Akebia Therapeutics shares in Q2 2026, an estimated $1.81K.
  • Akebia Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1920 holding.
  • CIBC Bancorp USA first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's Akebia Therapeutics position peaked at $72.8K in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.